--- a
+++ b/clusters/9knumclustersv2/clust_1547.txt
@@ -0,0 +1,11 @@
+Prior treatment\r\n* No more than two prior chemotherapy regimens in the metastatic setting\r\n* Prior treatment with fulvestrant in the metastatic setting is required, except for patients with a history of ER-negative metastatic breast cancer\r\n* Unlimited prior endocrine therapy regimens in the metastatic setting are allowed\r\n* No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor)
+Patients who have received prior administration of an Aurora A kinase targeted agent (including alisertib) are not eligible
+Prior administration of an aurora A kinase-targeted agent, including alisertib
+Any prior treatment with an aurora kinase inhibitor (either an aurora A kinase or pan-aurora kinase inhibitor)
+Prior treatment with Aurora A-targeted agents, including MLN
+Prior treatment with irinotecan or aurora A-targeted agents, including MLN
+Patient must not have received any previous treatment with any aurora-kinase inhibitors (MTD expansion cohort only)
+Prior administration of an aurora A kinase-targeted agent, including alisertib
+No prior Aurora kinase inhibitor
+Patients may not have received prior therapy with an Aurora kinase inhibitor
+Prior administration of an aurora A kinase-targeted agent, including alisertib